JP2021533796A - Ｂ７−ｈ７結合剤及びその使用方法 - Google Patents

Ｂ７−ｈ７結合剤及びその使用方法 Download PDF

Info

Publication number
JP2021533796A
JP2021533796A JP2021509746A JP2021509746A JP2021533796A JP 2021533796 A JP2021533796 A JP 2021533796A JP 2021509746 A JP2021509746 A JP 2021509746A JP 2021509746 A JP2021509746 A JP 2021509746A JP 2021533796 A JP2021533796 A JP 2021533796A
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021509746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533796A5 (https=
JPWO2020041300A5 (https=
Inventor
ジェル−ユアン シュー，
スザンヌ クリスティーン クローリー，
Original Assignee
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヌジーエム バイオファーマシューティカルス，インコーポレーテッド filed Critical エヌジーエム バイオファーマシューティカルス，インコーポレーテッド
Publication of JP2021533796A publication Critical patent/JP2021533796A/ja
Publication of JP2021533796A5 publication Critical patent/JP2021533796A5/ja
Publication of JPWO2020041300A5 publication Critical patent/JPWO2020041300A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021509746A 2018-08-21 2019-08-20 Ｂ７−ｈ７結合剤及びその使用方法 Pending JP2021533796A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720708P 2018-08-21 2018-08-21
US62/720,708 2018-08-21
PCT/US2019/047250 WO2020041300A1 (en) 2018-08-21 2019-08-20 B7-h7-binding agents and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2021533796A true JP2021533796A (ja) 2021-12-09
JP2021533796A5 JP2021533796A5 (https=) 2022-08-29
JPWO2020041300A5 JPWO2020041300A5 (https=) 2022-08-29

Family

ID=67841214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509746A Pending JP2021533796A (ja) 2018-08-21 2019-08-20 Ｂ７−ｈ７結合剤及びその使用方法

Country Status (7)

Country Link
US (1) US20210198366A1 (https=)
EP (1) EP3850009A1 (https=)
JP (1) JP2021533796A (https=)
CN (1) CN112930357A (https=)
AU (1) AU2019326438A1 (https=)
CA (1) CA3108905A1 (https=)
WO (1) WO2020041300A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025503772A (ja) * 2022-01-21 2025-02-04 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド 抗ｂ７－ｈ７抗体もしくはその抗原結合断片及び製造方法と応用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110760483B (zh) * 2019-11-08 2021-06-22 扬州大学 具牛、羊交叉反应的抗TNF-α单克隆抗体的制备及应用
WO2023173393A1 (zh) * 2022-03-18 2023-09-21 北京天广实生物技术股份有限公司 结合b7-h3的抗体及其用途
WO2025040144A1 (zh) * 2023-08-23 2025-02-27 南京再明医药有限公司 B7-h7抗原结合分子及其应用
CN119841949A (zh) * 2023-10-17 2025-04-18 科辉智药(深圳)新药研究中心有限公司 一种抗人hhla2的纳米抗体及其应用
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof
WO2025175056A1 (en) * 2024-02-15 2025-08-21 Nextpoint Therapeutics, Inc. Multispecific antibodies or antigen binding fragments thereof to b7-h7 and immune effector cell antigens
CN121005781A (zh) * 2024-05-24 2025-11-25 合肥天港免疫药物有限公司 高亲和力b7h7抗体或其抗原结合片段及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501814A (ja) * 2009-08-13 2013-01-17 ザ ジョンズ ホプキンス ユニバーシティー 免疫機能を調節する方法
US20160002337A1 (en) * 2013-03-01 2016-01-07 Albert Einstein College Of Medicine Of Yeshiva University Hhla2 as a novel inhibitor of human immune system and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015187359A1 (en) * 2014-06-04 2015-12-10 Ngm Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501814A (ja) * 2009-08-13 2013-01-17 ザ ジョンズ ホプキンス ユニバーシティー 免疫機能を調節する方法
US20160002337A1 (en) * 2013-03-01 2016-01-07 Albert Einstein College Of Medicine Of Yeshiva University Hhla2 as a novel inhibitor of human immune system and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025503772A (ja) * 2022-01-21 2025-02-04 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド 抗ｂ７－ｈ７抗体もしくはその抗原結合断片及び製造方法と応用

Also Published As

Publication number Publication date
AU2019326438A1 (en) 2021-03-04
CA3108905A1 (en) 2020-02-27
US20210198366A1 (en) 2021-07-01
EP3850009A1 (en) 2021-07-21
WO2020041300A1 (en) 2020-02-27
CN112930357A (zh) 2021-06-08

Similar Documents

Publication Publication Date Title
JP7834028B2 (ja) Ｉｌｔ結合剤及びその使用方法
US12187796B2 (en) ILT3-binding agents and methods of use thereof
JP6827415B2 (ja) 疾患の処置のための併用療法
JP2021533796A (ja) Ｂ７−ｈ７結合剤及びその使用方法
TWI564306B (zh) 雙特異性抗體
AU2013289990B2 (en) RSPO3 binding agents and uses thereof
US20180346571A1 (en) Pd-l1-binding agents and uses thereof
US20180222958A1 (en) Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
WO2018017864A2 (en) Pvrig-binding agents and uses thereof
US12240899B2 (en) LAIR-1-binding agents and methods of use thereof
CN109069639B (zh) Gitr抗体、方法及用途
CN116829186A (zh) 多特异性抗体及其用途
WO2023235706A1 (en) Combination therapies using ilt-binding agents and pd-1 inhibitors
TW202302626A (zh) 用於調節ｔｇｆ－ｂ信息傳導之細胞療法組成物及方法
RU2809746C2 (ru) Гуманизированное моноклональное антитело против vegf
JP2017526356A (ja) Ｒｓｐｏ１結合剤およびその使用
CN119947749A (zh) 多特异性抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240306